Alpha Cognition Inc
ACOG
株式のランク
#20188
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
株価
$8.47
最終同期: 2026-10-19
時価総額
$131.47M
変化（1日）
3.36%
変化（1年）
68.29%
国
US
取引 Alpha Cognition Inc (ACOG)
カテゴリー
Healthcare
Alpha Cognition Inc（ACOG）の利益
Jun 2026 時点の利益 TTM: 0.00
Alpha Cognition Inc の最新の財務報告によると、同社の現在の利益は 0.00 です。2022 年には $-12.11M の利益を上げ、これは 2021 年の利益 $-19.55M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Alpha Cognition Inc の利益の推移（2018 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2023 | $-13.77M | 13.68% |
| 2022 | $-12.11M | -38.02% |
| 2021 | $-19.55M | 237.90% |
| 2020 | $-5.78M | -12.45% |
| 2019 | $-6.61M | 20,254.71% |
| 2018 | $-32.46K | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
